Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Author Verified
RCT
ACE Report #444
Ace Report Cover General Orthopaedics

TNF antagonist better in treatment of early rheumatoid arthritis


Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

Lancet. 2009 Aug 8;374(9688):459-66.

Contributing Authors: RF van Vollenhoven S Ernestam P Geborek IF Petersson L Cöster E Waltbrand A Zickert J Theander A Thörner H Hellström A Teleman C Dackhammar F Akre K Forslind L Ljung R Oding A Chatzidionysiou M Wörnert J Bratt

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

258 patients with early stage rheumatoid arthritis, who were unresponsive to 4 months treatment with methotrexate, were randomized to receive additional treatment with Infliximab (tumor necrosis factor antagonist) or sulfasalazine and hydroxychloroquine. This trial assessed the efficacy of the use of tumor necrosis factor antagonists in treatment of rheumatoid arthritis, while comparing this treat...

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.